saude@vda.pt

14 a 18 de março de 2016

SAÚDE

REGULAÇÃO

MINISTÉRIO DA SAÚDE

Despacho n.º 3844-A/2016 - Diário da República n.º 52/2016, 1º Suplemento, Série II de 2016-03-15

Saúde - Gabinete do Secretário de Estado Adjunto e da Saúde

Determina a criação de um grupo de trabalho interinstitucional, que integra a Direção-Geral da Saúde, o Instituto Ricardo Jorge, o Infarmed e a Administração Central do Sistema de Saúde, no âmbito do Programa de Prevenção e Controlo de Infeções e de Resistência aos Antimicrobianos

Despacho n.º 3823/2016 - Diário da República n.º 52/2016, Série II de 2016-03-15

Saúde - Gabinete do Secretário de Estado Adjunto e da Saúde

Estabelece disposições para o processo de contratualização nos cuidados de saúde primários para 2016

INFARMED

Circular Informativa Conjunta n.º 2/2016/ACSS/INFARMED/SPMS – Esclarecimento à Circular Conjunta 1/2016/ACSS/INFARMED/SPMS

Publicação para efeitos do artigo 15º-A do Decreto -Lei n.º 176/2006, de 30 de Agosto - pedidos de **autorização de introdução no mercado de medicamentos genéricos**

EFPIA

Report - Enhancing Value in European Health Systems: The Role of Outcomes Measurement - Consensus Document

Health systems across the European Union are confronting numerous challenges – from ageing populations and the sustainable financing of health care, to wide variations in clinical practice, a necessary and increasing emphasis on patient experience, and significant public health problems. This report shows how a greater focus on health outcomes, and in particular the use of health outcome measures, can help to drive improvements across the health system – be it at the clinical level, the healthcare system level, or in relation to public health policies / interventions.

EMA

Human Medicines | Report: Report on the European network of paediatric research-European Medicines Agency workshop on gastrointestinal (GI) outcome measures to evaluate CFTR modulators for the treatment of cystic fibrosis (CF)

Human Medicines | Scientific guideline: Draft guideline on evaluation of anticancer medicinal products in man

The purpose of this guideline is to provide guidance on all stages of clinical drug development for the treatment of malignancies, including drug resistance modifiers or normal tissue protective compounds. Supportive measures such as anti-emetics and haematopoietic growth factors, however, are covered by separate guidelines.

Veterinary Medicines | Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2016

This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on

Human Medicines | Report: Assessment report for Article-5(3) procedure: Medicinal products under development for treatment of Ebola

Human Medicines | Report: Scientific recommendation on classification of advanced therapy medicinal products: Medicinal product composed of living, genetically modified Lactococcus lactis bacteria, containing the gene for anti-human tumor necrosis factor-alpha protein